Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes

Toxicology and Applied Pharmacology

Volumn 150, Issue 2, 1998, Pages 277-286

  Perrone, Carmen E ^a   Shao, Lihua ^a   Williams, Gary M ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

Apoptosis; DNA synthesis; Humn hepatocytes; Peroxisomal enzymes; Peroxisome proliferators; Rat hepatocytes

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CIPROFIBRATE; CLOFIBRATE; PEROXISOME PROLIFERATOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CULTURE; NONHUMAN; PEROXISOME; RAT; SPECIES DIFFERENCE; TECHNIQUE;

ANIMALIA; RODENTIA; TRIXIS;

EID: 0032102436     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1998.8413     Document Type: Article

References (53)

1. Althaus F. R., Lawrence S. D., Sattler G. L., Longfellow D. G., Pilot H. C. Chemical quantification of unscheduled DNA synthesis in cultured hepatocytes as an assay for the rapid screening of potential chemical carcinogens. Cancer Res. 42:1982;3010-3015.
2. Amacher D. E., Beck R., Schomaker S. J., Kenny C. V. Hepatic microsomal enzyme induction, β-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat. Toxicol. Appl. Pharmacol. 142:1997;143-150.
3. Baumgart E., Vanhooren J. C. T., Fransen M., Mannaerts G. P., Van Veldhoven P. P. Mammalian peroxisomal Acyl-CoA oxidases. Ann. NY Acad. Sci. 804:1996;678-679.
4. Bayly A. C., French N. J., Dive C., Roberts R. A. Non-genotoxic hepatocarcinogenesisin vitro: J. Cell Sci. 104:1993;307-315.
5. Bayly A. C., Roberts R. A., Dive C. Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator nafenopin. J. Cell Biol. 125:1994;197-203.
6. Bennett A. M., Williams G. M. Calcium as a permissive factor but not an initiation factor in DNA synthesis induction in cultured rat hepatocytes by the peroxisome proliferator ciprofibrate. Biochem. Pharmacol. 46:1993;2219-2227.
7. Bentley P., Calder I., Elcombe C., Grasso P., Stringer D., Wiegand H. J. Hepatic peroxisome proliferation in rodents and its significance for humans. Fed. Chem. Toxicol. 31:1993;857-907.
8. Bichet N., Cahard D., Fabre G., Remandet B., Gouy D., Cano J-P. Toxicological studies on a benzofuran derivative III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol. Appl. Pharmacol. 106:1984;509-517.
9. Budroe J. D., Umemura T., Angeloff K., Williams G. M. Dose-response relationships of hepatic acyl-CoA oxidase and catalase activity and liver mitogenesis induced by the peroxisome proliferator ciprofibrate in C57bl/6N and BALB/c mice. Toxicol. Appl. Pharmacol. 113:1992;192-198.
10. Budroe J. D., Williams G. M. Genotoxicity studies of peroxisome proliferators. Peroxisome: Biology and Importance in Toxicology and Medicine. 1993;Taylor and Francis, London. p. 525-568.
11. Butler E. G., England P. J., Williams G. M. Genetic differences in enzymes associated with peroxisome proliferation and hydrogen peroxide metabolism in inbred mouse strains. Carcinogenesis. 9:1988;1459-1463.
12. Cattley R. C., Marsman G., Popp J. A. Cell proliferation and promotion in the hepatocarcinogenicity of peroxisome proliferating chemicals. Mendelsohn M. L. Mutation and the Environment, Part D. 1990;123-132 Wiley-Liss, New York.
13. Chen H., Huang C., Wilson M. W., Lay L. T., Robertson L. W., Chow C. K., Glauert H. P. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on hepatic cell proliferation and toxicity in Sprague-Dawley rats. Carcinogenesis. 15:1994;2847-2850.
14. Cherkaoui M., Lone Y. C., Corral-Debrinski M., Latruffe N. Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators. Biochem. Biophys. Res. Commun. 173:1990;855-861.
15. Cornu-Chagnon M.-C., Dupont H., Edgar A. Fenofibrate: Metabolism and species differences of peroxisome proliferation in cultured hepatocytes. Fundam. Appl. Toxicol. 26:1995;63-74.
16. de la Iglesia F. A., Lewis J. E., Buchanan R. A., Marcus E. L., McMahon G. Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Artherosclerosis. 43:1982;19-37.
17. Dybing E., Mikalsen S-O. Peroxisome proliferation, genotoxicity and carcinogenicity. Peroxisome Proliferation and its Role in Carcinogenesis. 1995.
18. Eacho P. I., Lanier T. L., Brodhecker C. A. Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: Comparison of Wy14,643 to clofibric acid, nafenopin and LY171883. Carcinogenesis. 12:1991;1557-1561.
19. Elcombe C. R., Bell D. R., Elias E., Hasmall S. C., Plant N. J. Peroxisome proliferators: Species differences in response of primary hepatocyte cultures. Ann. NY Acad. Sci. 804:1996;628-635.
20. Eldridge S. R., Goldsworthy T. L., Popp J. A., Butterworth B. E. Mitogenic stimulation of hepatocellular proliferation in rodents following 1,4-dichlorobenzene administration. Carcinogenesis. 13:1992;409-415.
21. Foxworthy P. S., White S. L., Hoover D. M., Eacho P. I. Effect of ciprofibrate, bezafibrate and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 104:1990;386-394.
22. Garriot P., Barrat E., Drouin P., Genton P., Pointel J. P., Foliguet B., Kolopp M., Debry G. Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism. 36:1987;203-210.
23. Gavrieli Y., Sherman Y., Ben-Sasson S. A. Identification of programmed cell deathin situ. J. Cell Biol. 119:1992;493-501.
24. Ghanayem B. I., McIntyre T., Karam W. G. Induction of gene expression and DNA synthesis by WY14,643 (WY) in primary rat hepatocyte cultures co-cultured with non-parenchymal cells. Fundam. Appl. Toxicol. 36:1997;224.
25. Hanefeld M., Kemmer C., Kadner E. Relationship between morphological changes and lipid-lowering action of ρ-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Artherosclerosis. 46:1983;239-246.
26. 1. Carcinogenesis. 14:1993;145-149.
27. James N. H., Roberts R. A. The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes. Carcinogenesis. 15:1994;2687-2694.
28. Lalwani N. D., Reddy M. K., Qureshi S. A., Sirtori C. R., Abiko Y., Reddy J. K. Evaluation of selected hypolipidemic agents for the induction of peroxisomal enzymes and peroxisome proliferation in rat liver. Hum. Toxicol. 2:1983;27-48.
29. Lazarow P. B. Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol. 72:1981;315-319.
30. Lazarow P. B., de Duve C. A fatty acyl-CoA oxidizing system in rat liver peroxisomes: Enhancement by clofibrate, a hypolipidemic drug. Proc. Natl. Acad. Sci. USA. 73:1976;2043-2046.
31. Makowska J. M., Bonner F. W., Gibson G. G. Comparative induction of cytochrome p450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset. Arch. Toxicol. 65:1991;106-113.
32. Marsman D. S., Swanson-Pfeiffer C. L., Popp J. A. Lack of comitogenicity by the peroxisome proliferator hepatocarcinogens. Wy-14,643 and clofibric acid. Toxicol. Appl. Pharmacol. 122:1993;1-6.
33. Maslansky C. J., Williams G. M. Methods for the initiation and use of hepatocyte primary cultures from various species to detect metabolic activation of carcinogens. Webber M. M., Sekely L. I. In Vitro Models for Cancer Research. 1985;43-60 CRC Press, Boca Raton.
34. McQueen C. A., Williams G. M. Toxicology studies in cultured hepatocytes from various species. Rauckman E. J., Padilla G. M. The Isolated Hepatocyte: Use in Toxicology Xenobiotic and Biotransformations. 1987;51-67 Academic Press, New York.
35. Mennes W. C., Wortelboer H. M., Hassing G. A. M., van Sandwijk K., Timmerman A., Schmid B. P., Jahn U., Blaauboer B. J. Effects of clofibric and beclobric acid in rat and monkey hepatocyte primary culture: Influence on peroxisomal and mitochondrial beta-oxidation and the activity of catalase, glutathione-S. Arch. Toxicol. 68:1994;506-511.
36. Mitchell A. M., Bridges J. W., Elcombe C. R. Factors influencing peroxisome proliferation in cultured rat hepatocytes. Arch. Toxicol. 55:1984;239-246.
37. Oberhammer F. A., Fritsch G., Pavelka M., Froschl G., Tiefenbacher R., Purchio T., Schulte-Herman R. Induction of apoptosis in cultured hepatocytes and in the regressing liver by transforming growth factor-β1 occurs without activation of an endonuclease. Toxicol. Lett. 64/65:1992;701-704.
38. Oberhammer F. A., Qin H-M. Effect of three tumour promoters on the stability of hepatocyte cultures and apoptosis after transforming growth factor-β1. Carcinogenesis. 16:1995;1363-1371.
39. Palmer C. N. A., Hsu M.-H., Griffin K. J., Raucy J. L., Johnson E. F. Peroxisome proliferator activated receptor-α expression in human liver. Mol. Pharmacol. 53:1998;14-22.
40. Rao M. S., Reddy J. K. An overview of peroxisome proliferator-induced hepatocarcinogenesis. Environ. Health Perspect. 93:1991;205-209.
41. Rao M. S., Reddy J. K. Hepatocarcinogenesis of peroxisome proliferators. Ann. NY Acad. Sci. 804:1996;573-587.
42. Reddy J. K., Chu R. Peroxisome proliferator-induced pleiotropic responses: Pursuit of a phenomenon. Ann. NY Acad. Sci. 804:1996;176-201.
43. Reddy J. K., Lalwani N. D. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. CRC Crit. Rev. Toxicol. 12:1983;1-58.
44. Rhodes C., Orton T. C., Pratt I. S., Batten P. L., Bratt H., Jackson S. J., Elcombe C. R. Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl)phthalate (DEHP) in rats and marmosets: Extrapolation of effects in rodents to man. Environ. Health Perspect. 65:1986;299-308.
45. Richert L., Price S., Chesne C., Maita K., Carmichael N. Comparison of the induction of hepatic peroxisome proliferation by the herbicide oxadiazonin vivoin vitro. Toxicol. Appl. Pharmacol. 141:1996;35-43.
46. Roberts R. A. Non-genotoxic hepatocarcinogenesis: Suppression of apoptosis by peroxisome proliferators. Ann. NY Acad. Sci. 804:1996;588-611.
47. Roberts R. A., Soames A. R., Gill J. H., James N. H., Wheeldon E. B. Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different hepatocyte populations. Carcinogenesis. 16:1995;1693-1698.
48. Rose M. L., Germolec D., Schoonhoven R., Thurman R. G. Increase hepatocyte proliferation predominantly by mechanisms involving Kupffer cells. Fundam. Appl. Toxicol. 36:1997;123.
49. Seglen P. O. Preparation of rat liver cells. Exp. Cell Res. 82:1973;391-398.
50. Schwartz M. K., Bodansky O. Lactic dehydrogenase (clinical aspects). Methods in Enzymol. 9:1966;294-302.
51. Small G. M., Burdett K., Connock M. J. A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. Biochem. J. 227:1985;205-210.
52. Tugwood J. D., Aldridge T. C., Lambe K. G., Macdonald N., Woodyatt N. J. Peroxisome proliferator activated receptor: Structures and functions. Ann. NY Acad. Sci. 804:1996;252-265.
53. Yeldandi A. V., Milano M., Subbarao V., Reddy J. K., Rao M. S. Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis. Cancer Lett. 47:1989;21-27.